-
Product Insights
New![]()
Net Present Value Model: Atea Pharmaceuticals Inc’s AT-752
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Atea Pharmaceuticals Inc’s Bemnifosbuvir sulfate
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Atea Pharmaceuticals Inc's Bemnifosbuvir sulfate Drug Details: AT-527 is under development for the treatment of chronic Hepatitis C viral infections and coronavirus COVID-19...
-
Product Insights
New![]()
Net Present Value Model: Atea Pharmaceuticals Inc’s Ruzasvir + Bemnifosbuvir Sulfate
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Atea Pharmaceuticals Inc – Company Profile
Atea Pharmaceuticals Inc (Atea) is a clinical stage biopharmaceutical company. The company develops, discovers, and commercializes therapies for treatment of life-threatening viral infections. It utilizes purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, ssRNA, viruses. Atea’s product pipeline includes AT-527, a direct-acting antiviral drug candidate to treat covid-19, AT-752 for treatment of dengue and AT-787 for Hepatitis C (HCV). The company is also investigating AT-889 and AT-934 drug programs for the treatment of...
Add to Basket -
Company Profile
![]()
Atea ASA – Company Profile
Atea ASA (Atea) offers IT infrastructure services and related solutions to businesses. It provides various solutions, including hybrid platform, digital workplace and information management. The company delivers IT products from vendors and assists its customers with IT infrastructure services. Its hardware and software solutions include communication and networks, video and web conferencing, unified communication solutions, and mobility, PCs, tablets, smartphones, printers, servers, data storage, virtualization and management. Atea also provides shared services, including consulting services, cloud related services, logistics, global...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ruzasvir in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ruzasvir in Hepatitis C Drug Details: Ruzasvir is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STP-122G in Thrombosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STP-122G in Thrombosis Drug Details: STP-122G is under development for the treatment of bleeding...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HZN-457 in Gouty Arthritis (Gout)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HZN-457 in Gouty Arthritis (Gout) Drug Details: HZN-457 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bemnifosbuvir Sulfate in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bemnifosbuvir Sulfate in Hepatitis C Drug Details: AT-527 is under development for the treatment...
-
Product Insights
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dengue Fever Pipeline Drugs Market Report Overview Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style. The dengue fever pipeline...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
![]()
Net Present Value Model: AT-752
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AT-752 Drug Details AT-752 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – AT-752
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AT-752 Drug Details AT-752 is under development for the treatment of patients either newly...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ruzasvir
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ruzasvir Drug Details Ruzasvir is under development for the treatment of hepatitis C infection....
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – bemnifosbuvir sulfate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry bemnifosbuvir sulfate Drug Details AT-527 is under development for the treatment of chronic Hepatitis...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hepatitis C occurs with multiple symptoms including abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The Hepatitis C pipeline drugs market research report provides an analysis of the Hepatitis C drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.